<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>33(4)</volume><submitter>Suuring M</submitter><pubmed_abstract>Cell therapy is a promising approach for inducing tolerance and thus reducing the use of immunosuppressive drugs in several immune-mediated conditions. Tolerogenic dendritic cells (tolDCs) regulate antigen-specific tolerance and control the immune response, making them an interesting candidate for cell therapy. Over the last years, different human tolDCs have been generated &lt;i>ex vivo&lt;/i>, each with specific phenotypic and functional characteristics. This study aims to highlight the impact of the manufacturing process on tolDC function. For that, two well-known tolDCs, autologous tolerogenic dendritic cells (ATDCs) and interleukin (IL)-10-induced dendritic cells (DC-10s), were compared based on their phenotype, metabolic secretion, transcriptomic profile, and their modulatory function. Our</pubmed_abstract><journal>Molecular therapy. Methods &amp; clinical development</journal><pagination>101605</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12589953</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Protocol of generation of tolerogenic dendritic cells affects their transcriptional and metabolic profiles leading to specific tolerogenic functions.</pubmed_title><pmcid>PMC12589953</pmcid><pubmed_authors>Lavercan D</pubmed_authors><pubmed_authors>Chiffoleau E</pubmed_authors><pubmed_authors>Cloteau C</pubmed_authors><pubmed_authors>Croyal M</pubmed_authors><pubmed_authors>Rouel M</pubmed_authors><pubmed_authors>Suuring M</pubmed_authors><pubmed_authors>Gregori S</pubmed_authors><pubmed_authors>Raux A</pubmed_authors><pubmed_authors>Delhaye T</pubmed_authors><pubmed_authors>Royer AL</pubmed_authors><pubmed_authors>Santoni de Sio F</pubmed_authors><pubmed_authors>Rondeau D</pubmed_authors><pubmed_authors>Moreau A</pubmed_authors><pubmed_authors>Amodio G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Protocol of generation of tolerogenic dendritic cells affects their transcriptional and metabolic profiles leading to specific tolerogenic functions.</name><description>Cell therapy is a promising approach for inducing tolerance and thus reducing the use of immunosuppressive drugs in several immune-mediated conditions. Tolerogenic dendritic cells (tolDCs) regulate antigen-specific tolerance and control the immune response, making them an interesting candidate for cell therapy. Over the last years, different human tolDCs have been generated &lt;i>ex vivo&lt;/i>, each with specific phenotypic and functional characteristics. This study aims to highlight the impact of the manufacturing process on tolDC function. For that, two well-known tolDCs, autologous tolerogenic dendritic cells (ATDCs) and interleukin (IL)-10-induced dendritic cells (DC-10s), were compared based on their phenotype, metabolic secretion, transcriptomic profile, and their modulatory function. Our</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-05T14:44:45.623Z</modification><creation>2026-05-18T03:08:20.463Z</creation></dates><accession>S-EPMC12589953</accession><cross_references><pubmed>41210169</pubmed><doi>10.1016/j.omtm.2025.101605</doi></cross_references></HashMap>